Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 41.95 -0.59%
SRRK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.14B
- EPS (TTM)
- -$3.32
- Dividend yield
- None
- 52-week range
- 27.07 – 61.76
- Day range
- 41.96 – 44.20
- Volume / Avg
- 1.56M / 1.49M
- Beta
- —
- Shares outstanding
- 121.79M
52-week range
SRRK stock today
Scholar Rock (SRRK) closed at $42.20 on Oct 7, down 0.59% (-$0.25), versus the S&P 500's 0.22% decline. At this level, SRRK sits in the middle of its 52-week range of $27.07 to $61.76: 31.7% below the high, set on Aug 26, 2026 and 55.9% above the low. SRRK is down 4.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 6.8%.
Scholar Rock has posted a net loss over the last twelve months (EPS of -$3.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Scholar Rock
Company profileScholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. David L. Hallal
- Headquarters
- Cambridge, MA
- Employees
- 289
- IPO year
- 2018
- Website
- scholarrock.com
Financial highlights
Full financialsIn fiscal 2025, Scholar Rock generated $0 in revenue. Scholar Rock reported a net loss of $377.9 million, compared with a loss of $246.3 million a year earlier. Diluted earnings per share came in at -$3.29.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | — | — | $33.19M | $18.82M |
| Growth | — | — | — | +76.41% | +22.16% |
| Net income | $-377.94M | $-246.29M | $-165.79M | $-134.50M | $-131.80M |
| EPS (diluted) | $-3.29 | $-2.47 | $-1.99 | $-2.26 | $-3.59 |
Analyst forecast
ForecastConsensus (18 analysts)
strong_buy
Avg. price target
$70.44+66.92%
- Strong buy 2
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.84 vs —
Scholar Rock peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs SRRK |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs SRRK |
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs SRRK |
| IOVAIovance Biotherapeutics Inc. | 12.92 | -0.35% | $5.85B | vs SRRK |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs SRRK |
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs SRRK |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs SRRK |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs SRRK |
Indexes, lists and sector
Scholar Rock stock FAQ
What is Scholar Rock's stock price today?
SRRK last traded at $42.20 as of Oct 7, 4:00 PM EDT, down 0.59% on the day. Prices are delayed at least 15 minutes.
Who is Scholar Rock's CEO?
Mr. David L. Hallal is the chief executive officer of Scholar Rock Holding Corporation, which has about 289 employees.
What is the SRRK 52-week high?
The 52-week high for SRRK is $61.76 and the 52-week low is $27.07. The stock is currently 31.7% below its high.